Clinical Trial Detail

NCT ID NCT03911869
Title An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis (POLARIS)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Array BioPharma
Indications

melanoma

Therapies

Binimetinib + Encorafenib

Age Groups: adult senior

Additional content available in CKB BOOST